These policy recommendations that cover FOC strategies are provided by pharmaceutical companies both just before and after NICE TA recommendations are printed. This coverage steering will examine FOC schemes before and following NICE TA publication independently as they have got distinct concerns.For medicines at present commissioned by NHS England